Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071364
Filing Date
2025-05-14
Accepted
2025-05-14 16:05:31
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mura-20250331.htm   iXBRL 10-Q 2046544
2 EX-31.1 mura-ex31_1.htm EX-31.1 18654
3 EX-31.2 mura-ex31_2.htm EX-31.2 18705
4 EX-32.1 mura-ex32_1.htm EX-32.1 10912
5 EX-32.2 mura-ex32_2.htm EX-32.2 10964
  Complete submission text file 0000950170-25-071364.txt   7246034

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mura-20250331.xsd EX-101.SCH 941747
69 EXTRACTED XBRL INSTANCE DOCUMENT mura-20250331_htm.xml XML 1089766
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41837 | Film No.: 25945326
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)